| 000 | 01604 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516160609.0 | ||
| 264 | 0 | _c20131029 | |
| 008 | 201310s 0 0 eng d | ||
| 022 | _a1473-5741 | ||
| 024 | 7 |
_a10.1097/CAD.0b013e328363adc5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCiruelos, Eva | |
| 245 | 0 | 0 |
_aRole of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. _h[electronic resource] |
| 260 |
_bAnti-cancer drugs _cSep 2013 |
||
| 300 |
_a769-80 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAndrostadienes _xadministration & dosage |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aAromatase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xmetabolism |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aEverolimus |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aSirolimus _xadministration & dosage |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aCortes-Funes, Hernán | |
| 700 | 1 | _aGhanem, Ismael | |
| 700 | 1 | _aManso, Luis | |
| 700 | 1 | _aArteaga, Carlos | |
| 773 | 0 |
_tAnti-cancer drugs _gvol. 24 _gno. 8 _gp. 769-80 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/CAD.0b013e328363adc5 _zAvailable from publisher's website |
| 999 |
_c22903229 _d22903229 |
||